Invention Grant
- Patent Title: Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
-
Application No.: US16908487Application Date: 2020-06-22
-
Publication No.: US10995088B2Publication Date: 2021-05-04
- Inventor: Caroline Springer , Richard Marais , Dan Niculescu-Duvaz , Leo Leung , Deborah Smithen , Cedric Callens , Haoran Tang
- Applicant: The Institute of Cancer Research: Royal Cancer Hospital
- Applicant Address: GB London
- Assignee: The Institute of Cancer Research: Royal Cancer Hospital
- Current Assignee: The Institute of Cancer Research: Royal Cancer Hospital
- Current Assignee Address: GB London
- Priority: GB1602934 20160219
- Main IPC: C07D417/12
- IPC: C07D417/12 ; A61P35/00 ; C07D263/46 ; C07D277/46 ; C07D277/36 ; C07D333/18 ; C07D333/34 ; C07D409/12 ; C12Q1/37 ; C07D277/26
Abstract:
Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
Public/Granted literature
- US20210040078A1 Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer Public/Granted day:2021-02-11
Information query
